Accupril
(Quinapril)ApprovedSmall molecule
PfizerQuinapril is a medication that helps lower blood pressure and treat heart failure by relaxing blood vessels, allowing blood to flow more easily and reducing the workload on the heart.[2] Accupril is currently approved and in use across 4 indications[4].[1]
Accupril is one of 130 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.
4
Indications
8
Total Trials
0
Active Trials
129
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Accupril
PfizerApproved
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertensive2 trials
Myocardial Ischemia1 trial
Peripheral Neuropathy1 trial
Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus
Completed·—·Phase 4·NCT03031834
Neuropathy1 trial
Diabetic Autonomic Neuropathy and Left Ventricular Function
Completed·—·Phase 4·NCT05713396·59 enrolled
2 more indications
Effectiveness1 trial
Regulatory
FDA Approval Timeline[5]
Nov 19, 1991
ACCUPRIL
NDA NDA019885
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Accupril drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Quinapril. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]